New advances in typhoid fever vaccination strategies

Advances in Experimental Medicine and Biology

Volumn 697, Issue , 2011, Pages 17-39

  Bhutta, Zulfiqar A ^a   Khan, M Imran ^b   Soofi, Sajid Bashir ^b   Ochiai, R Leon ^b  

^a AGA KHAN UNIVERSITY   (Pakistan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BACTERIAL VACCINE; CEFTRIAXONE; CEPHALOSPORIN; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; DIPHTHERIA TOXOID TYPHOID FEVER CONJUGATE VACCINE; NALIDIXIC ACID; OFLOXACIN; TYPHOID VACCINE; UNCLASSIFIED DRUG; TYPHOID PARATYPHOID VACCINE;

ANTIBIOTIC RESISTANCE; ARTICLE; AWARENESS; BACTERIAL STRAIN; BACTERIUM DETECTION; CHINA; CLINICAL FEATURE; COST OF ILLNESS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG CHOICE; DRUG COST; DRUG DETERMINATION; DRUG MARKETING; FEVER; GEOGRAPHIC DISTRIBUTION; HIGH RISK POPULATION; HOSPITAL COST; HUMAN; INDIA; INFECTION CONTROL; LABORATORY TEST; MEDICAL INFORMATION; MOLECULAR PATHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RASH; RISK ASSESSMENT; RISK FACTOR; SALMONELLA TYPHI; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; SOUTHEAST ASIA; TREATMENT PLANNING; TYPHOID FEVER; VACCINATION; VIET NAM; VOMITING; HEALTH; IMMUNOLOGY; ISOLATION AND PURIFICATION; MASS IMMUNIZATION; REVIEW;

COMMUNICABLE DISEASE CONTROL; DRUG RESISTANCE, BACTERIAL; HUMANS; MASS VACCINATION; RISK FACTORS; SALMONELLA TYPHI; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES; WORLD HEALTH;

EID: 79952277642     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-7185-2_3     Document Type: Article

References (86)

1. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. N Engl J Med. 2002 Nov 28;347(22):1770-82.
2. Bhan MK, Bahl R, Bhatnagar S. Typhoid and paratyphoid fever. Lancet. 2005 Aug 27-Sep 2;366(9487):749-62.
3. Eberth. Oranismen in den Organen bei. Typhus abdominalis. Virchows Arch Path Anal. 1880;81:16.
4. Skerman VBD, McGowan V, Sneath PHA. Approved lists of bacterial names. Int J Syst Bacteriol. 1980;30:195.
5. Gaffky. Aetiologie des Abdominaltyphus: Mittheilungen aus dem kaiserlichen Gesundheitsante. Feischsgesundheitsamt. 1884;48.
6. Edwards PR, Ewing WH. Identification of Enterobacteriaceae. Minneapolis, MN: Bugess Publishing Co; 1972.
7. Felix A, Pitt RM. A new antigen of B. typhosus. Lancet. 1934 July 28;224(5787):6.
8. Wong KH, Feeley JC, Northrup RS, Forlines ME. Vi antigen from Salmonella typhosa and immunity against typhoid fever. I. Isolation and immunologic properties in animals. Infect Immun. 1974 Feb;9(2):348-53.
9. Mehta G, Arya SC. Capsular Vi polysaccharide antigen in Salmonella enterica serovar typhi isolates. J Clin Microbiol. 2002 Mar;40(3):1127-8.
10. Robbins JD, Robbins JB. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J Infect Dis. 1984 Sep;150(3):436-49.
11. Crump JA, Luby SP,Mintz ED. The global burden of typhoid fever. BullWorld Health Organ. 2004 May;82(5):346-53.
12. Ivanoff B, Levine MM, Lambert PH. Vaccination against typhoid fever: present status. Bull World Health Organ. 1994;72(6):957-71.
13. Crump JA, Ram PK, Gupta SK, MillerMA, Mintz ED. Part I. Analysis of data gaps pertaining to Salmonella enterica serotype typhi infections in low and medium human development index countries, 1984-2005. Epidemiol Infect. 2008 Apr;136(4):436-48.
14. Ochiai RL, Acosta CJ, Danovaro-HollidayMC, Baiqing D, Bhattacharya SK, AgtiniMD et al. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull World Health Organ. 2008 Apr;86(4):260-8.
15. DeRoeck D, Jodar L, Clemens J. Putting typhoid vaccination on the global health agenda. N Engl J Med. 2007 Sep 13;357(11):1069-71.
16. Brooks WA, Hossain A, Goswami D, Nahar K, Alam K, Ahmed N et al. Bacteremic typhoid fever in children in an urban slum, Bangladesh. Emerg Infect Dis. 2005 Feb;11(2): 326-9.
17. Sinha A, Sazawal S, Kumar R, Sood S, Reddaiah VP, Singh B et al. Typhoid fever in children aged less than 5 years. Lancet. 1999 Aug 28;354(9180):734-37.
18. Siddiqui FJ, Rabbani F, Hasan R, Nizami SQ, Bhutta ZA. Typhoid fever in children: some epidemiological considerations from Karachi, Pakistan. Int J Infect Dis. 2006 May;10(3): 215-22.
19. Saha SK, Baqui AH, Hanif M, Darmstadt GL, Ruhulamin M, Nagatake T et al. Typhoid fever in Bangladesh: implications for vaccination policy. Pediatr Infect Dis J. 2001 May;20(5): 521-4.
20. Vollaard AM, Ali S, van Asten HA, Widjaja S, Visser LG, Surjadi C et al. Risk factors for typhoid and paratyphoid fever in Jakarta, Indonesia. JAMA. 2004 June 2;291(21): 2607-15.
21. Edelman R, Levine MM. Summary of an international workshop on typhoid fever. Rev Infect Dis. 1986 May-Jun;8(3):329-49.
22. Maskey AP, Basnyat B, Thwaites GE, Campbell JI, Farrar JJ, Zimmerman MD. Emerging trends in enteric fever in Nepal: 9124 cases confirmed by blood culture 1993-2003. Trans R Soc Trop Med Hyg. 2008 Jan;102(1):91-5.
23. Uneke CJ. Concurrent malaria and typhoid fever in the tropics: the diagnostic challenges and public health implications. J Vector Borne Dis. 2008 Jun;45(2):133-42.
24. Butler T, Islam A, Kabir I, Jones PK. Patterns of morbidity and mortality in typhoid fever dependent on age and gender: review of 552 hospitalized patients with diarrhea. Rev Infect Dis. 1991 Jan-Feb;13(1):85-90.
25. Chatterjee H, Jagdish S, Pai D, Satish N, Jayadev D, Reddy PS. Changing trends in outcome of typhoid ileal perforations over three decades in Pondicherry. Trop Gastroenterol. 2001 July- Sep;22(3):155-8.
26. Mweu E, English M. Typhoid fever in children in Africa. Trop Med Int Health. 2008 Apr;13(4):532-40.
27. Thaver D, Zaidi AK, Critchley JA, Azmatullah A, Madni SA, Bhutta ZA. Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever). Cochrane Database Syst Rev. 2008;4:CD004530.
28. Akpede GO, Akenzua GI. Management of children with prolonged fever of unknown origin and difficulties in the management of fever of unknown origin in children in developing countries. Paediatr Drugs. 2001;3(4):247-62.
29. Yang J. Enteric Fever in South China: Guangxi Province. J Infect Dev Ctries. 2008;2(4):6.
30. Gil R, Alvarez JL, Gomez C, Alvaro A, Gil A. Epidemiology of typhoid and paratyphoid fever hospitalizations in Spain (1997-2005). Hum Vaccin. 2009 June;5(6):420-4.
31. Shukla S, Patel B, Chitnis DS. 100 years of Widal test & its reappraisal in an endemic area. Indian J Med Res. 1997 Feb;105:53-7.
32. Vallenas C, Hernandez H, Kay B, Black R, Gotuzzo E. Efficacy of bone marrow, blood, stool and duodenal contents cultures for bacteriologic confirmation of typhoid fever in children. Pediatr Infect Dis. 1985 Sep-Oct;4(5):496-8.
33. Bhutta ZA, Naqvi SH, Razzaq RA, Farooqui BJ. Multidrug-resistant typhoid in children: presentation and clinical features. Rev Infect Dis. 1991 Sep-Oct;13(5):832-6.
34. Naheed A, Ram PK, Brooks WA, Mintz ED, Hossain MA, Parsons MM et al. Clinical value of Tubex and Typhidot rapid diagnostic tests for typhoid fever in an urban community clinic in Bangladesh. Diagn Microbiol Infect Dis. 2008 Aug;61(4):381-6.
35. Chang JE, Hernandez H, Yi A, Chea E, Chaparro E, Matos E et al. [Hemoculture and bone marrow culture in children with typhoid fever]. Bol Med Hosp Infant Mex. 1982 Sep;39(9):614-16.
36. Whitaker JA, Franco-Paredes C, del Rio C, Edupuganti S. Rethinking typhoid fever vaccines: implications for travelers and people living in highly endemic areas. J Travel Med. 2009 Jan- Feb;16(1):46-52.
37. Tarr PE, Kuppens L, Jones TC, Ivanoff B, Aparin PG, Heymann DL. Considerations regarding mass vaccination against typhoid fever as an adjunct to sanitation and public health measures: potential use in an epidemic in Tajikistan. Am J Trop Med Hyg. 1999 Jul;61(1):163-70.
38. Levine MM, Lepage P. Prevention of typhoid fever. Adv Exp Med Biol. 2005;568: 161-73.
39. Barreto ML, Genser B, Strina A, Teixeira MG, Assis AM, Rego RF et al. Effect of citywide sanitation programme on reduction in rate of childhood diarrhoea in northeast Brazil: assessment by two cohort studies. Lancet. 2007 Nov 10;370(9599):1622-8.
40. Stanton BF, Clemens JD. An educational intervention for altering water-sanitation behaviors to reduce childhood diarrhea in urban Bangladesh. II. A randomized trial to assess the impact of the intervention on hygienic behaviors and rates of diarrhea. Am J Epidemiol. 1987 Feb;125(2):292-301.
41. Luby SP, Agboatwalla M, Feikin DR, Painter J, Billhimer W, Altaf A et al. Effect of handwashing on child health: a randomised controlled trial. Lancet. 2005 Jul 16- 22;366(9481):225-33.
42. Fewtrell L, Kaufmann RB, Kay D, Enanoria W, Haller L, Colford JM Jr. Water, sanitation, and hygiene interventions to reduce diarrhoea in less developed countries: a systematic review and meta-analysis. Lancet Infect Dis. 2005 Jan;5(1):42-52.
43. Guzman CA, Borsutzky S, Griot-Wenk M, Metcalfe IC, Pearman J, Collioud A et al. Vaccines against typhoid fever. Vaccine. 2006 May 1;24(18):3804-11.
44. Griffin GE. Typhoid fever and childhood vaccine strategies. Lancet. 1999 Aug 28;354(9180):698-9.
45. Whittington D, Sur D, Cook J, Chatterjee S, Maskery B, Lahiri M et al. Rethinking cholera and typhoid vaccination policies for the poor: private demand in Kolkata, India. World Dev. 2009 Feb;37(2):399-409.
46. Do GC,Whittington D, Le TK, Utomo N, Nguyen TH, Poulos C et al. Household demand for typhoid fever vaccines in Hue, Vietnam. Health Policy Plan. 2006 May;21(3):241-55.
47. DeRoeck D, Clemens JD, Nyamete A, Mahoney RT. Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia. Vaccine. 2005 Apr 15;23(21):2762-74.
48. Hoffman SL, Punjabi NH, Kumala S, Moechtar MA, Pulungsih SP, Rivai AR et al. Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone. N Engl J Med. 1984 Jan 12;310(2):82-8.
49. Gupta B, Kumar R, Khurana S. Multi drug resistant Salmonella typhi in Ludhiana (Punjab). Indian J Pathol Microbiol. 1993 Jan;36(1):5-7.
50. Mirza SH, Beeching NJ, Hart CA. Multi-drug resistant typhoid: a global problem. J Med Microbiol. 1996 May;44(5):317-19.
51. Kato Y, Fukayama M, Adachi T, Imamura A, Tsunoda T, Takayama N et al. Multidrugresistant typhoid fever outbreak in travelers returning from Bangladesh. Emerg Infect Dis. 2007 Dec;13(12):1954-5.
52. Coovadia YM, Gathiram V, Bhamjee A, Garratt RM, Mlisana K, Pillay N et al. An outbreak of multiresistant Salmonella typhi in South Africa. Q J Med. 1992 Feb;82(298):91-100.
53. Woodward TE, Smadel JE et al. Preliminary report on the beneficial effect of chloromycetin in the treatment of typhoid fever. Ann Intern Med. 1948 Jul;29(1):131-4.
54. Olarte J, Galindo E. Salmonella typhi resistant to chloramphenicol, ampicillin, and other antimicrobial agents: strains isolated during an extensive typhoid fever epidemic in Mexico. Antimicrob Agents Chemother. 1973 Dec;4(6):597-601.
55. Bahl R, Sinha A, Poulos C, Whittington D, Sazawal S, Kumar R et al. Costs of illness due to typhoid fever in an Indian urban slum community: implications for vaccination policy. J Health Popul Nutr. 2004 Sep;22(3):304-10.
56. Wright AE, LeishmanW. Remarks on the results which have been obtained by the antityphoid inoculations and on the methods which have been employed in the preparation of the vaccine. Br Med J. 1900;1:8.
57. Hawley PR, Simmons JS. The effectiveness of vaccines used for the prevention of typhoid fever in the United States army and navy. Am J Public Health Nations Health. 1934 Jul;24(7):689-709.
58. Frawley JM. The treatment of typhoid fever in children by means of lysed vaccine. Cal West Med. 1938 Jun;48(6):415-17.
59. Siler JF, Dunham GC. Duration of immunity conferred by typhoid vaccine: results of revaccination by intracutaneous injection of typhoid vaccine. Am J Public Health Nations Health. 1939 Feb;29(2):95-103.
60. Raettig H. [Indication for vaccination against typhoid fever.]. Dtsch Med Wochenschr. 1954 Jan 29;79(5):173-4.
61. Warren JW, Hornick RB. Immunization against typhoid fever. Ann Rev Med. 1979;30: 457-72.
62. Levine MM, Ferreccio C, Cryz S, Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet. 1990 Oct 13;336(8720):891-4.
63. Simanjuntak CH, Paleologo FP, Punjabi NH, Darmowigoto R, Soeprawoto, Totosudirjo H et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet. 1991 Oct 26;338(8774):1055-9.
64. Engels EA, Lau J. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev. 2000;2:CD001261.
65. Fraser A, Paul M, Goldberg E, Acosta CJ, Leibovici L. Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials. Vaccine. 2007 Nov 7;25(45): 7848-57.
66. Wang JY, Noriega FR, Galen JE, Barry E, Levine MM. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909. Infect Immun. 2000 Aug;68(8):4647-52.
67. Tacket CO, Ferreccio C, Robbins JB, Tsai CM, Schulz D, Cadoz M et al. Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines. J Infect Dis. 1986 Aug;154(2):342-5.
68. Acharya IL, Lowe CU, Thapa R, Gurubacharya VL, Shrestha MB, Cadoz M et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N Engl J Med. 1987 Oct 29;317(18):1101-4.
69. Klugman KP, Gilbertson IT, Koornhof HJ, Robbins JB, Schneerson R, Schulz D et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet. 1987 Nov 21;2(8569):1165-9.
70. Tacket CO, Levine MM, Robbins JB. Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever. Vaccine. 1988 Aug;6(4): 307-8.
71. Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine. 1996 Apr;14(5):435-8.
72. Arya SC. Efficacy of Salmonella typhi Vi capsular polysaccharide vaccine in South Africa. Vaccine. 1997 Feb;15(2):244.
73. Chen X, Stanton B, Pach A, Nyamete A, Ochiai RL, Kaljee L et al. Adults' perceived prevalence of enteric fever predicts laboratory-validated incidence of typhoid fever in children. J Health Popul Nutr. 2007 Dec;25(4):469-78.
74. Kaljee LM, Pham V, Son ND, Hoa NT, Thiem VD, Canh do G et al. Trial participation and vaccine desirability for Vi polysaccharide typhoid fever vaccine in Hue City, Viet Nam. Trop Med Int Health. 2007 Jan;12(1):25-36.
75. Bodhidatta L, Taylor DN, Thisyakorn U, Echeverria P. Control of typhoid fever in Bangkok, Thailand, by annual immunization of schoolchildren with parenteral typhoid vaccine. Rev Infect Dis. 1987 Jul-Aug;9(4):841-5.
76. Yang HH Experience of school based vaccination in typhoid fever endemic area using Vi manufactured in China. Typhoid Fever, a Neglected Disease: Towards a Vaccine Introduction Policy, Annecy, 2-4 April 2007.
77. Acosta CJ, Galindo CM, Ochiai RL, Danovaro-Holliday MC, Page AL, Thiem VD et al. The role of epidemiology in the introduction of vi polysaccharide typhoid fever vaccines in Asia. J Health Popul Nutr. 2004 Sep;22(3):240-5.
78. Yang J, Acosta CJ, Si GA, Zeng J, Li CY, Liang DB et al. A mass vaccination campaign targeting adults and children to prevent typhoid fever in Hechi; expanding the use of Vi polysaccharide vaccine in southeast China: a cluster-randomized trial. BMC Publ Health. 2005 May;18(5):49.
79. Acosta CJ, Galindo CM, Ali M, Elyazeed RA, Ochiai RL, Danovaro-Holliday MC et al. A multi-country cluster randomized controlled effectiveness evaluation to accelerate the introduction of Vi polysaccharide typhoid vaccine in developing countries in Asia: rationale and design. Trop Med Int Health. 2005 Dec;10(12):1219-28.
80. Agtini MD, Ochiai RL, Soeharno R, Lee HJ, Sundoro J, Hadinegoro SR et al. Introducing Vi polysaccharide typhoid fever vaccine to primary school children in North Jakarta, Indonesia, via an existent school-based vaccination platform. Publ Health. 2006 Nov;120(11):1081-7.
81. Khan MI, Ochiai RL, Hamza HB, Sahito SM, Habib MA, Soofi SB et al. Lessons and implications from a mass immunization campaign in squatter settlements of Karachi, Pakistan: an experience from a cluster-randomized double-blinded vaccine trial [NCT00125047]. Trials. 2006;7:17.
82. Sur D, Ochiai RL, Bhattacharya SK, Ganguly NK, Ali M, Manna B et al. A clusterrandomized effectiveness trial of Vi typhoid vaccine in India. N Engl J Med. 2009 Jul 23;361(4):335-44.
83. Wahdan MH, Sérié C, Cerisier Y, Sallam S, Germanier R. A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results. J Infect Dis. 1982 Mar;145(3):292-5.
84. Levine MM, Ferreccio C, Black RE, Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet. 1987 May 9;1(8541):1049-52.
85. Black RE, Levine MM, Ferreccio C, Clements ML, Lanata C, Rooney J, Germanier R. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Chilean Typhoid Committee. Vaccine. 1990 Feb;8(1):81-4.
86. Yang HH, Wu CG, Xie GZ, Gu QW, Wang BR, Wang LY, Wang HF, Ding ZS, Yang Y, Tan WS, Wang WY, Wang XC, Qin M, Wang JH, Tang HA, Jiang XM, Li YH, Wang ML, Zhang SL, Li GL. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. Bull World Health Organ. 2001;79(7):625-31.